The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura

Basit Öğe Kaydı
dc.contributor.authorPasa, Semir
dc.contributor.authorAltintas, Abdullah
dc.contributor.authorCil, Timucin
dc.contributor.authorDanis, Ramazan
dc.contributor.authorAyyildiz, Orhan
dc.date.accessioned2024-04-24T16:02:21Z
dc.date.available2024-04-24T16:02:21Z
dc.date.issued2009
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe most difficult problem a physician encounters is the management of patients with idiopathic thrombocytopenic purpura (ITP), who has persistent severe thrombocytopenia after failure of initial treatment with glucocorticoids and splenectomy. Most of the patients refractory to corticosteroids and splenectomy will become refractory to other available agents, such as intravenous immunoglobulin (IVIg), danazol or chemotherapy. In this study, we investigated the effect of rituximab on 17 splenectomized refractory chronic ITP patients. Here, we showed that the anti-CD20 antibody, rituximab, induces a clinically significant response in severe chronic ITP patients, who are unresponsive to other therapeutic options. After sixth month, 10 out of 14 responders were still maintaining their durable and significant platelet responses (platelet counts > 50 x 10(9)/l), without requirement to any other ITP medication. Therefore, we suggest that, rituximab is an effective treatment option in splenectomized refractory or relapsed ITP patients. Rituximab was well tolerated without severe side effects.en_US
dc.identifier.doi10.1007/s11239-008-0208-z
dc.identifier.endpage333en_US
dc.identifier.issn0929-5305
dc.identifier.issn1573-742X
dc.identifier.issue3en_US
dc.identifier.pmid18311541
dc.identifier.scopus2-s2.0-64749110159
dc.identifier.scopusqualityQ1
dc.identifier.startpage329en_US
dc.identifier.urihttps://doi.org/10.1007/s11239-008-0208-z
dc.identifier.urihttps://hdl.handle.net/11468/14754
dc.identifier.volume27en_US
dc.identifier.wosWOS:000264886300011
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Thrombosis and Thrombolysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRefractory Chronic Idiopathic Thrombocytopenic Purpuraen_US
dc.subjectSplenectomyen_US
dc.subjectAnti-Cd20 Monoclonal Antibodyen_US
dc.subjectRituximaben_US
dc.titleThe efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpuraen_US
dc.titleThe efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu